Join us in Houston for the 2024 DTRF Together We Will Weekend and RFA Walk. - Register Today!

The Desmoid Tumor Research Foundation

August 2014

Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.

Author Information

Armelle Dufresne,David Pérol,Héloïse Philippon,Jean Yves Blay,Laurent Alberti,Mehdi Brahmi,Sarah Kabani

Cancer Research Center of Lyon, INSERM UMR 1052, CNRS UMR 5286, Centre Leon Berard, 28 rue Laënnec, Lyon, France.a.dufresne@hotmail.com.

Publication

Summary

The phase II "Desminib trial" included 40 patients with AF to evaluate the toxicity and efficacy of imatinib resulting in a 65% tumor control rate at 1 year. We investigated a potential predictive value of KIT exon 10 M541L variant (KITL541) on this prospective series.

View Abstract